Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis (Q34065266)

30 July 2017

0 references

Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis (English)

1 reference

30 July 2017

0 references

1 reference

1 reference

Chun S Kwok

2

0 references

Sonal Singh

object named as

Sonal Singh

5

0 references

Yoon K Loke

6

object named as

Yoon K Loke

1 reference

30 July 2017

Richard M Turner

1

1 reference

30 July 2017

Chen Chen-Turner

3

1 reference

30 July 2017

Chinedu A Maduakor

4

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 August 2014

1 reference

British Journal of Clinical Pharmacology

30 July 2017

1 reference

30 July 2017

78

1 reference

30 July 2017

258-273

1 reference

30 July 2017

2

1 reference

Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?

30 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Pioglitazone--do we really need it to manage type 2 diabetes?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Examining the safety of PPAR agonists - current trends and future prospects

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Epidemiology and risk factors of urothelial bladder cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Pioglitazone and bladder cancer: a propensity score matched cohort study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Pioglitazone and bladder cancer: a population-based study of Taiwanese.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

When to publish measures of disproportionality derived from spontaneous reporting databases?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Bladder cancer in 2010: how far have we come?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Effects of PPARgamma and combined agonists on the urinary tract of rats and other species

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

When can odds ratios mislead?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4137819

Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers

5 July 2018

1 reference

Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat.

21 January 2018

1 reference

Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.

21 January 2018

1 reference

Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.

21 January 2018

1 reference

Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan

21 January 2018

1 reference

Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study

21 January 2018

1 reference

Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event

21 January 2018

1 reference

Analysing Data and Undertaking Meta-Analyses

21 January 2018

1 reference

FDA panel advises easing restrictions on rosiglitazone

21 January 2018

1 reference

12 December 2020

Pioglitazone and bladder cancer

1 reference

12 December 2020

Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes

1 reference

12 December 2020

Rosiglitazone is not associated with an increased risk of bladder cancer

1 reference

12 December 2020

Flip flop policy over pioglitazone licence causes media storm in India

1 reference

12 December 2020

Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!

1 reference

12 December 2020

Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus

1 reference

12 December 2020

More on influenza vaccine in young children

1 reference

12 December 2020

Identifiers

DOI

10.1111/BCP.12306

1 reference

30 July 2017

1 reference

30 July 2017

1 reference